A Randomized Phase II Study to Determine the Effect of 2 Different Doses AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma.

Trial Profile

A Randomized Phase II Study to Determine the Effect of 2 Different Doses AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 18 Mar 2013 Planned end date changed from 1 Apr 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top